Cabaletta Bio: Q3 Earnings Insights
Portfolio Pulse from Benzinga Insights
Cabaletta Bio (NASDAQ:CABA) reported its Q3 earnings, beating estimated earnings by 7.5% with an EPS of $-0.37 versus an estimate of $-0.4. However, revenue was down $0 from the same period last year. Last quarter, the company beat on EPS by $0.07, which was followed by an 11.0% increase in the share price the next day.
November 09, 2023 | 12:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cabaletta Bio's Q3 earnings beat estimates, but revenue was down. Last quarter's EPS beat led to an 11% share price increase.
Cabaletta Bio's earnings beat estimates, which is generally a positive signal for investors and can lead to an increase in the stock price. However, the decrease in revenue could be a concern. The company's past performance shows that a beat on EPS led to an 11% increase in the share price, which could potentially happen again.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100